摘要
目的:研究丙戊酸钠对精神分裂症首发和复发治疗增效作用差异。方法:本次纳入2017年6月-2019年5月本院收治的精神分裂症患者66例展开研究,根据疾病发作情况分为首发组(n=36)、复发组(n=30),两组均接受丙戊酸钠治疗。将两组的阳性和阴性精神症状评定量表评分、认知功能评分、社会功能评分、临床疗效、不良反应发生情况进行比对。结果:两组患者组间治疗前、治疗8周后的PANSS评分、MoCA评分、PSP评分进行比较,差异无统计学意义(P>0.05),两组组内治疗8周后的PANSS评分、PSP评分均低于治疗前,MoCA评分高于治疗前,差异具有统计学意义(P<0.05);两组患者的治疗总有效率、不良反应发生率进行比较,差异无统计学意义(P>0.05)。结论:对首发、复发精神分裂症患者使用丙戊酸钠治疗的增效作用显著,精神症状、认知功能及社会功能得到了显著改善,且安全性高。
Objective:To study the difference of synergistic effect of Sodium Valproate on the first episode and relapse of schizophrenia.Method:A total of 66 schizophrenic patients admitted to our hospital from June 2017 to May 2019 were included in this study,and they were divided into the first group(n=36)and the relapse group(n=30)according to the disease attack,and both groups were treated with Sodium Valproate.The positive and negative mental symptom rating scale score,cognitive function score,social function score,clinical efficacy and adverse reactions of the two groups were compared.Result:There were no significant differences in PANSS score,MOCA score and PSP score between the two groups before and 8 weeks after treatment(P>0.05).The PANSS score and PSP score 8 weeks after treatment in the two groups were lower than those before treatment,while MOCA score was higher than that before treatment,with statistical significance(P<0.05).The total effective rate and incidence of adverse reactions in the two groups were compared,the differences were not statistically significant(P>0.05).Conclusion:The efficacy of Sodium Valproate in the treatment of first episode and recurrent schizophrenia is significant,the mental symptoms,cognitive function and social function have been significantly improved,and the safety is high.
作者
陈晓兰
CHEN Xiaolan(Youxi Hospital of Traditional Chinese Medicine,Youxi 365100,China)
出处
《中外医学研究》
2021年第17期31-33,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
精神分裂症
丙戊酸钠
精神症状
认知功能
Schizophrenia
Sodium Valproate
Psychiatric symptoms
Cognitive function
